Form 4: Pfizer Director Suzanne Nora Johnson Acquires Phantom Stock

Pfizer Inc. director Suzanne Nora Johnson acquired 7,686.539 phantom stock units as part of deferred director compensation.

Summary

• Director Suzanne Nora Johnson was granted 7,686.539 phantom stock units on April 23, 2026.
• The units were issued under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Each unit represents one phantom share of common stock valued at $26.67 per unit.
• Following this transaction, the director's total beneficial ownership of phantom stock units is 116,982.649.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation, having no material impact on the company's financial outlook.

Positives

• Director alignment with company performance through equity-based compensation.
• Standard deferred compensation practice for non-employee directors.

Negatives

• None identified.

Risks

• Value of phantom stock units is subject to the future market performance of Pfizer common stock.

Future Outlook

The units are settled in cash or common stock at the director's election following their retirement from the Board of Directors.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation within the pharmaceutical sector, reflecting standard corporate governance practices for board members.

Comparison to Industry Standards

• The use of phantom stock units for director compensation is a common practice among large-cap pharmaceutical companies like Merck, Bristol Myers Squibb, and Eli Lilly to align board interests with long-term shareholder value.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard component of director remuneration.

Next Steps

• Settlement of units upon the director's future retirement from the Board.

Key Dates

Keywords

Pfizer, PFE, Director Compensation, Insider Transaction, Phantom Stock, SEC Form 4